Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.
PYC Therapeutics Limited has applied for quotation of 10,573,060 new fully paid ordinary shares on the Australian Securities Exchange, with an issue date of March 9, 2026. The additional securities, issued under a previously announced transaction, will expand the company’s quoted share capital and may influence its market liquidity and ownership structure for existing and prospective investors.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code PYC. The company operates in the therapeutics sector, focusing on the development of medical treatments and related technologies for commercial and clinical markets.
Average Trading Volume: 952,906
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.46B
See more data about PYC stock on TipRanks’ Stock Analysis page.